InsidersTradesSigma
Follow the Remus Pharmaceuticals Limited share price and the full directors' dealings record of the company, a listed equity based in India. Shares are quoted on the IN market, under the oversight of SEBI (PIT + SAST). Operating in the Health Care sector, Remus Pharmaceuticals Limited has logged 214 insider filings. Market capitalisation: €7.4bn. The latest transaction was disclosed on 12 January 2026 (Purchase). Among the most active insiders: Renosen Pharmaceuticals Private Limited. All data is accessible without an account.
214
Insider Decl.
n/a
Thresholds
€3m
211 ops.
Buy Volume
€33,430
3 ops.
Sell Volume
10Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,859 of 29,062 companies
49.5
score / 100
Value51
Quality48
FCF yld0.5%
Earn yld5.0%
EV/EBITDA12.1x
ROE·
Gross mgn13%
Net mgn4.3%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 January 2026
Declarations214 total
2,600 shares@ ₹708.65100.0% of flowEquity SharesSEBI:f9eec4f56a6bd0156c33c8d538907c7efef2196c
1,200 shares@ ₹737.201.3% of flowEquity SharesSEBI:1ed48e6902256a8acb5babae583d722504dfbb7f
500 shares@ ₹751.580.4% of flowEquity SharesSEBI:8536e571a6c83a6c14cb994159fc90b28cebf536
500 shares@ ₹721.009.7% of flowEquity SharesSEBI:026fef6719e40deb77212a329355812dc464af21
500 shares@ ₹723.3733.7% of flowEquity SharesSEBI:7ee7397f590cec5f66709bcfe02bc9eac2311ba9
200 shares@ ₹730.000.1% of flowEquity SharesSEBI:255ac3578df38b9d99108bb545ad7b1d3c3105d8
3,000 shares@ ₹800.004.8% of flowEquity SharesSEBI:a844cfbefac12ef8a32eb347c489d6e4d79a2711
200 shares@ ₹854.7254.7% of flowEquity SharesSEBI:39fe14adf6b4d9ff5c8eeabd2d3e3c565e432eab
400 shares@ ₹1,984.120.9% of flowEquity SharesSEBI:f695d17363a1c38e2e5b31c218c6a64cab453828
200 shares@ ₹2,027.330.5% of flowEquity SharesSEBI:a0f7b85c06a2054c90323f30eb97f185a4e06962
50 shares@ ₹2,385.0013.1% of flowEquity SharesSEBI:4fc18aa0321c694da71d079c45eac39716519bbb
50 shares@ ₹2,403.5613.1% of flowEquity SharesSEBI:57109d788856327ca4cb135ce23d38d2de9d583e
50 shares@ ₹2,525.0013.9% of flowEquity SharesSEBI:f27a65dfe9fcc09fe469b100a7071d04383ec149
50 shares@ ₹2,425.0013.3% of flowEquity SharesSEBI:57d2854ce7d7fa8f0598f290ddddca139d458ad8
50 shares@ ₹2,345.0012.8% of flowEquity SharesSEBI:6409aec7439c636afe5b5d2aa1eda450278f3e07
100 shares@ ₹2,688.950.4% of flowEquity SharesSEBI:3fc3d7cdaf5c391116f88032770954f41b5ebc60
400 shares@ ₹2,689.001.8% of flowEquity SharesSEBI:c1de8f1f1850ace35d1e9d8461198bf8dca172b0
500 shares@ ₹2,689.002.2% of flowEquity SharesSEBI:252b1906a72072fe6ae413f5f5d1b5a6599e48a2
100 shares@ ₹2,379.000.3% of flowEquity SharesSEBI:3a2659fb138bc1e53d9fa32ccc6b3649120ab801
300 shares@ ₹2,371.600.8% of flowEquity SharesSEBI:497032be8b5382fde6d8f7e61e504d6f6e9291a0
100 shares@ ₹2,393.000.3% of flowEquity SharesSEBI:12caf91c095ea315c4fd9e432f0c8cf8cf95caad
100 shares@ ₹2,369.000.3% of flowEquity SharesSEBI:6f162052571e4876a29e2cf72e55c43a3e7bd6fa
300 shares@ ₹2,405.000.8% of flowEquity SharesSEBI:9a0852ad46f853b3917002f2a1b332ee8b509bef
2,000 shares@ ₹2,276.405.3% of flowEquity SharesSEBI:51cb63b91d267ab74d4d053e4b8370023a67049e
1,000 shares@ ₹2,035.002.4% of flowEquity SharesSEBI:9b2ed14c3b8ea12df9bbe9aadd489562522a24ee
25 of 214 declarations
关于 Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited是一家专注于在医疗保健和制药领域开发创新药物的公司。该公司在XBOM上市。